Esperion Therapeutics Inc. Tuesday announced positive results from a Phase 2a study of its drug candidate ETC-1002 when added to statin therapy in patients with high levels of low density lipoprotein cholesterol, the so-called bad cholesterol, in their blood.
Esperion Therapeutics’ proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.
Ranbaxy Pharmaceuticals Inc. has recalled several doses of its generic version of Lipitor because some batches of the cholesterol fighter may contain small glass particles.
It’s a new drug that’s hoped will do what no other drug can: Significantly raise the levels of good cholesterol in patients.
Think about this: It might be time to swap out that daily bagel.
Can eating an apple a day really keep the doctor away?
An experimental drug boosted good cholesterol so high and dropped bad cholesterol so low in a study that doctors were stunned and voiced renewed hopes for an entirely new way of preventing heart attacks and strokes.
High blood lipids are a big risk factor for developing heart disease, which is the leading cause of death in the United States. Approximately one of every six adult Americans has high blood cholesterol and […]
A global team of researchers co-led by the University of Michigan School of Public Health has discovered or confirmed 95 regions of the human genome where genetic variants are associated with blood cholesterol and triglyceride […]
The European Union has approved a new chewable form of cholesterol blockbuster Lipitor for children 10 and up with high levels of bad cholesterol and triglycerides, a type of blood fat, Pfizer said Tuesday. The […]